Cancer Immunotherapy Market Report 2026

The cancer immunotherapy market size has grown rapidly in recent years. It will grow from $124.09 billion in 2025 to $137.99 billion in 2026 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to breakthroughs in tumor immunology, rising global cancer incidence, early success of monoclonal antibodies, increased oncology R&D funding, regulatory approvals for checkpoint inhibitors.

The cancer immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $210.39 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to growing adoption of CAR T-cell therapies, expansion into solid tumor indications, increasing investment in cancer vaccines, rising demand for targeted combination therapies, supportive reimbursement policies for immunotherapy. Major trends in the forecast period include rapid adoption of immune checkpoint inhibitors, growing use of combination immunotherapy regimens, expansion of cell-based cancer therapies, rising focus on personalized immunotherapy, increasing number of oncology clinical trials.

The increasing incidence of cancer is anticipated to drive the growth of the cancer immunotherapy market. Factors contributing to the rising number of cancer cases worldwide include tobacco use, alcohol consumption, obesity, sedentary lifestyles, and environmental influences. This escalation in cancer prevalence is expected to increase demand for cancer immunotherapies, as patients are increasingly seeking treatment options that offer higher recovery potential with minimal discomfort. For example, in July 2024, projections released by Cancer Research UK, a UK-based cancer charity, indicated that cancer incidence rates in the United Kingdom are expected to rise for most cancer types between 2023-2025 and 2038-2040, with increases ranging from less than 1% for breast cancer to as high as 50% for eye cancer, while a limited number of cancers are projected to decline, with reductions ranging from 2% for lung cancer to 27% for mesothelioma. Consequently, the growing incidence of cancer is expected to stimulate demand for cancer immunotherapy during the forecast period.

Leading companies operating in the cancer immunotherapy market are concentrating on the development of advanced solutions such as PD-1 immunotherapies to broaden access to immune-based treatment options for patients with difficult-to-treat cancers. PD-1 immunotherapies are immune checkpoint-based treatments designed to enhance antitumor immune responses by inhibiting interactions within the programmed death-1 pathway. For example, in August 2025, Intas Pharmaceuticals, an India-based pharmaceutical company focused on oncology and biologics, introduced HETRONIFLY (serplulimab). This therapy became the first programmed death-1 inhibitor globally approved for extensive-stage small cell lung cancer and employs a dual-targeting mechanism against PD-L1 and PD-L2 with strong receptor internalization to improve immune activation. Its proven survival benefits and significantly lower cost compared with existing immunotherapies highlight its clinical importance and help expand patient access to advanced cancer treatments in India.

In July 2024, Boehringer Ingelheim, a Germany-based pharmaceutical company, acquired Nerio Therapeutics for $1.3 billion. Through this acquisition, Boehringer Ingelheim aims to strengthen its immuno-oncology portfolio by incorporating Nerio’s innovative preclinical program centered on immune checkpoint inhibitors. Nerio Therapeutics is a US-based biotechnology company specializing in drug discovery and development, with a particular focus on phosphatases, a complex yet highly promising class of therapeutic protein targets.

Major companies operating in the cancer immunotherapy market are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc., Kura Oncology Inc.

North America was the largest region in the cancer immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the cancer immunotherapy market by increasing costs of imported biologic raw materials, cell culture media, viral vectors, and specialized manufacturing equipment. These impacts are most significant for monoclonal antibodies and cell therapy segments and in regions reliant on cross-border biopharmaceutical supply chains such as Asia-Pacific and parts of Europe. Higher tariffs have increased therapy development and production costs, potentially limiting patient access. However, tariffs are also driving investments in domestic biologics manufacturing and strengthening local supply chains for advanced cancer therapies.

The cancer immunotherapy market research report is one of a series of new reports that provides cancer immunotherapy market statistics, including cancer immunotherapy industry global market size, regional shares, competitors with a cancer immunotherapy market share, detailed cancer immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the cancer immunotherapy industry. This cancer immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cancer immunotherapy is a form of cancer treatment that enhances the body’s natural defenses to fight the disease. The immune system helps protect the body against infections and other illnesses and is composed of white blood cells, organs, and tissues of the lymphatic system. Cancer immunotherapy is available in several forms, including cytokines and vaccines, adoptive cell therapies, oncolytic viruses, tumor-infecting viruses, and others.

The primary product types in cancer immunotherapy include monoclonal antibodies, checkpoint inhibitors, immunomodulators, vaccines, and cell therapies. Monoclonal antibodies are laboratory-produced proteins that function within the immune system in a manner similar to natural human antibodies. Cancer immunotherapy is used in the treatment of lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, and multiple myeloma, and is administered in hospitals, cancer research centers, and clinics.

The cancer immunotherapy market includes revenues earned by entities by helping the immune system fight cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.